Cbre 2025 Life Sciences Outlook

Cbre 2025 Life Sciences Outlook. News Release CBRE 2024 US Life Sciences Outlook Wave of LabConstruction Completions Will Life sciences lab and R&D property sales dropped to their lowest level in more than a decade in 2024, primarily due to high interest rates and weak supply-and-demand fundamentals, according to CBRE However, improving macroeconomic conditions, increased demand, and lower interest rates could lead to greater investment sales activity in 2025.

A surge of new lab/R&D supply will be the life sciences market's biggest challenge in the first half of 2025 before tapering off later in the year Find a Property Find a Property CBRE are global leaders in commercial property, both to rent and for sale.

Cbre 2024 Life Sciences Outlook Alidia Thomasine

With more than 140,000 professionals (including Turner & Townsend employees) in over 100 countries, CBRE is the global leader in commercial real estate services and investment. With more than 140,000 professionals (including Turner & Townsend employees) in over 100 countries, CBRE is the global leader in commercial real estate services and investment. Looking at 2025, CBRE and Cushman & Wakefield are forecasting.

Employment Trends & Outlook CBRE. On the other hand, global venture capital increased (as did mergers and acquisitions), U.S An uptick in venture funding in Q4 2022 was a hopeful sign for employment stabilization later this year since employment changes generally mirror funding changes after a two-quarter lag.

Life Sciences Innovation and Expansion CBRE. economy, improving capital markets and growing life sciences employment are supporting momentum in several lab/R&D real estate indicators Total life sciences lab/R&D leasing activity in the nation's 13 largest markets increased to 2.9 million sq